LucidQuest published the latest Respiratory Strategic Roundup covering developments from 31 July to 3 September 2026, highlighting a shift toward differentiation in respiratory treatment markets.

LucidQuest helps biopharma, healthtech, and investors make faster, higher-confidence decisions with decision-grade intelligence. We combine: Primary intelligence (KOL, payer, patient, and market stakeholder research) Real-time conference coverage (previews, live tracking, and strategic debriefs across major congresses) AI-powered, human-in-the-loop wargames and workshops to test strategy under uncertainty Tech-enabled monitoring and analysis supported by proprietary tools Our work supports high-stakes choices from R&D through commercialization, plus investment diligence, translating complex signals into clear recommendations teams can act on. We bring deep scientific training and hands-on experience across biopharma and healthcare technology, including AI and digital health, and we operate globally through an expert network spanning regions and therapy areas. Let’s connect if you need primary intelligence, congress coverage, a competitive wargame, or strategic advisory. Specialties: strategy consulting, strategic and competitive intelligence, business strategy, strategic marketing, scenario planning, venture capital, digital health, mHealth, eHealth, Internet of Everything, vaccines, immunotherapies, gene therapy, cell therapy, cardiovascular, HIV/AIDS, biofinance, biotechnology, pharmaceuticals, business and financial modelling, patient centricity, respiratory and infectious diseases, oncology, pre-clinical and clinical development, molecular biology, immunology, social media